Despite many recent advances in cancer treatments with breakthrough therapies, a large proportion of patients unfortunately develop resistance to their current treatment and are in need of new options. We at ORIC are committed to addressing this unmet medical need.

Our commitment includes conducting clinical trials with our investigational medicines to demonstrate their safety and efficacy. Data from these clinical trials ultimately could support regulatory approval, allowing them to become available for the benefit of many cancer patients.

Patients who choose to participate in clinical trials play a critical role in the development of these and other new medicines. If you are interested in gaining access to our investigational medicines, we encourage you to speak with your physician about the possibility of enrolling in a clinical trial.

The list below provides information on clinical trials of ORIC new product candidates that are currently recruiting patients:

  • An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors  Study Identifier: NCT03928314
  • An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide  Study Identifier: NCT04033328